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Some of the toxic effects of smoking have been attributed to the combustion of nitrogenous protein in
tobacco. The effects of a treatment which reduces tobacco’s protein nitrogen level, on the in vitro cytotox-
icity and genotoxicity of cigarette smoke particulate matter (PM), were measured. PMs were tested in the
Neutral Red Uptake (NRU) test; the Salmonellamutagenicity assay (SAL); the mouse lymphoma mamma-
lian cell mutation assay (MLA) and the in vitro micronucleus test (IVMNT). PMs from all of the cigarettes
were cytotoxic and genotoxic. PM obtained from smoking treated tobacco, showed a small, consistent
and statistically signiﬁcant reduced mutagenicity (revertants/lg) in TA98 with post-mitochondrial
supernatant (S9). No consistent quantitative or qualitative differences were detected in the other tests.
The data are discussed in relation to published information on smoke chemistry obtained from cigarettes
made of tobacco treated using this technique. The observations conﬁrm that the method did not give rise
to any new qualitative or quantitative cytotoxic or genotoxic effects, and may have reduced PM’s bacte-
rial mutagenicity in TA98 with S9. Further toxicity testing is warranted, to investigate the effects of the
tobacco treatment in more detail and add to the data already obtained.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Proteins and amino acids have been reported to be precursors
for a number of potentially toxic constituents of tobacco
smoke, including aromatic amines (2-aminonaphthalene and 4-
aminobiphenyl) (Torikaiu et al., 2005) and mutagenic heterocyclic
amines (Clapp et al., 1999; Matsumoto and Yoshida, 1981;ritish American Tobacco; BT,
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Y-NC-ND license.Mizusaki et al., 1977), the latter being implicated as a primary
source of PM genotoxicity (DeMarini et al., 2008).
This paper describes an investigation into the in vitro assay re-
sponses of cigarette smoke PM from cigarettes containing tobacco
which had been subject to a novel tobacco blend treatment (BT)
(Liu et al., 2011). The effect of the blend treatment process is to re-
duce levels of soluble and insoluble proteins, amino acids and
water soluble polyphenols, such as chlorogenic acid, rutin and
scopoletin in tobacco.
The BT process is carried out on cut tobacco, and involves the
sequential extraction of the tobacco with water and an aqueous
protease enzyme solution, followed by addition to the resulting
solution of adsorbents and then reapplication of the soluble mate-
rials to the extracted tobacco. The treated tobacco retains the
structure of original tobacco, is designed to be used with an adsor-
bent ﬁlter, to create a cigarette with a conventional appearance,
usage, and smoking experience (Liu et al., 2011). The effect of the
BT process on the yields of mainstream and sidestream smoke tox-
icants from cigarettes made with this tobacco and smoked under
International Standards Organisation (ISO) smoking conditions
(ISO 3308:1977) are described elsewhere (Liu et al., 2011). The
smoke composition of the BT cigarettes compared in this study
demonstrated reduced levels of a range of smoke constituents,
including ammonia, hydrogen cyanide, aromatic amines and some
phenols; consistent with the aims of the BT process.
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PM samples, from cigarettes containing BT ﬂue-cured tobacco, to
four in vitro toxicity assays. These assays – the Neutral Red Uptake
(NRU) assay, the Salmonella mutagenicity assay (SAL), the mouse
lymphoma mammalian cell mutation assay (MLA) and the
in vitro micronucleus test (IVMNT) – have been validated and
accepted by regulatory agencies, including the International
Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) and the
Organisation of Economic Cooperation and Development (OECD)
(Aardema et al., 2006; Anon., 2006, 1990; Corvi et al., 2008;
Garriott et al., 2002; Gatehouse et al., 1990; ICH, 1995, 1997;
Kirsch-Volders et al., 2003; Matsushima et al., 1999; OECD, 2010,
1997a,b; Phelps et al., 2002); and recommended by the Coopera-
tion Centre for Scientiﬁc Research Relative to Tobacco (CORESTA)
Task Force In Vitro Toxicity Testing of Tobacco Smoke (CORESTA,
2010; 2003).2. Materials and methods
2.1. Test materials
PM preparation was as described by McAdam et al. (2011).
Brieﬂy, cigarettes were conditioned according to ISO 3402 (1999),
then smoked on a RM20CSR smoking machine (Borgwalt-KC, Ham-
burg, Germany) according to ISO 3308 (2000). An appropriate
number of cigarettes were smoked to obtain approximately
300 mg PM on a 44 mm Cambridge ﬁlter pad. PM was eluted in di-
methyl sulphoxide (DMSO) to a concentration of 24 mg/ml and
stored protected from light in single-use aliquots at 80 C. Fresh
samples of PM were prepared for each study.
For the external laboratory providing the MLA, PM was deliv-
ered frozen (80 C).
PMs were tested under code, as follows: W860, W861, W862,
W863, W864, M4A and 2R4F (Table 1). The series W860–W864
represents different cigarette designs. Any effects of BT tobacco
would be seen in general comparisons of PMs with (W862, W863
and W864) and without BT tobacco (W860 and W861), and also
the speciﬁc comparison of W862 (80% BT tobacco) and its control,
W861 (no BT tobacco).2.2. In vitro toxicology testing
Post-mitochondrial supernatant (S9), prepared from male
Sprague Dawley rats, induced with Aroclor 1254, was used for
metabolic activation.Table 1
Composition of different cigarettes smoked to yield PM test products.
PM/cigarette code Blend
W860 Untreated BT tobaccoa (80%)/Stemb (20%)
W861 Untreated BT tobaccoa (80%)/Stemb (20%)
W862 BT Tobaccof (80%)/Stemb (20%)
W863 BT Tobaccof (80%)/Stemb (20%)
W864 Flue-cured laminaa (40%)/BT Tobaccof (40%)/Stemb (20%
M4Ag Flue-cured blend
2R4Fh United States (US)-style blend
a Leaf tobacco.
b Mid-rib of leaf.
c Cellulose acetate as found in conventional cigarettes.
d Ion exchange resin ﬁlter additive to selectively adsorb some smoke constituents.
e Coconut shell derived activated carbon to adsorb some volatile components.
f Tobacco treated to remove some of the protein and phenols by the method describe
g M4A is British American Tobacco’s (BAT’s) historical control.
h Reference cigarettes to provide historical control data (2R4F was originally obtainedThe NRU cytotoxicity assay was performed as described by
McAdam et al. (2011). Brieﬂy, V79 cells were maintained in tissue
culture in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supple-
mented with 10% (v/v) heat inactivated foetal calf serum and pen-
icillin/streptomycin (0.52% v/v). Cytotoxicity was expressed as a
reduction in the uptake of Neutral Red dye into the lysosomes of
cells after 48 h culture, measured by absorbance at 450 nm. Serial
dilutions of PM were made to determine concentration-dependent
inhibition of V79 cell growth. Four separate assays were performed
for each test substance and the concentration causing 50% toxicity
in the NRU test (IC50) values were derived by software analysis of
the dose–response curves obtained. This protocol conforms to the
guidelines issued by the National Institutes of Health (NIH) (NIH,
2001). A higher IC50 value represents a lower cytotoxicity. One-
way analysis of variance (ANOVA) was used to detect any signiﬁ-
cant differences between IC50 concentrations for the different test
materials.
The SAL mutagenicity test was performed as described by
McAdam et al. (2011), using ﬁve Salmonella typhimurium strains:
TA98, TA100, TA102, TA1535 and TA1537, in the presence and ab-
sence of S9. All tests were performed in duplicate. A further two
tests using strains TA98, TA100 and TA1537 in the presence of S9
were carried out over the linear portion of the dose–response
curve. All data were analysed using Dunnett’s test for signiﬁcant
differences between solvent control plates and those treated with
PM. The numbers of revertants per lg PM were calculated using
data from the linear part of the dose–response curve. Subse-
quently, Tukey’s statistic was used to compare speciﬁc activities
of the PMs. This protocol complied with OECD guideline 471
(OECD, 1997a) and ICH guidelines (ICH, 1995, 1997).
The IVMNT was performed as described by McAdam et al.
(2011). Brieﬂy, duplicate V79 cell cultures in DMEM supplemented
with 10% foetal calf serum, were pulsed with test or control sam-
ples for 3 h followed by a 17 h recovery, with and without S9, or
for 20 h without S9. At least six dose levels for each PM were
scored for cytotoxicity and for micronucleus formation in bi-nucle-
ate cells, on duplicate slides. Differences between micronucleated
binucleated cells (MnBn) at the different test concentrations and
the solvent controls were subjected to paired t-tests. This method
complied with OECD draft guideline 487 (OECD, 2004).
The MLA was performed as described by McAdam et al. (2011),
using L5178Y thymidine kinase (tk) +/- cells cultured in Roswell
Park Memorial medium (RPMI). There were two independent
experiments using a 3 h exposure with S9; and two independent
experiments used 3 and 24 h exposures without S9; each with
duplicate treatment cultures. After a two day expression period,
cells were grown for eight days, and then triﬂuoro-thymidineFilter
Cellulose acetatec
Cellulose acetatec/cavity with CR20d (40 mg) and charcoale (20 mg)
Cellulose acetatec/cavity with CR20d (40 mg) and charcoale(20 mg)
Cellulose acetatec/cavity with charcoale (60 mg)
) Cellulose acetatec/cavity with charcoale (60 mg)
Cellulose acetatec
Cellulose acetatec
d.
from the University of Kentucky).
Table 2
IC50 values for PMs W860–W864.
PM
source
IC50 (lg NFDPM/ml) in four experiments
1 2 3 4 Mean Standard deviation
(SD)
W860 19.55 21.52 33.33 33.60 27.00 7.51
W861 19.88 20.27 23.79 31.49 23.86 5.38
W862 23.27 24.88 21.46 34.14 25.94 5.64
W863 20.60 27.04 21.29 32.17 25.28 5.43
W864 22.38 23.39 60.88a 30.99 25.59 4.71
a Value omitted from statistical analysis due to possible error in sample
preparation.
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OECD Guideline 476 (OECD, 1997b). PMs were compared in terms
of the slopes of their responses.Table 3
Mutagenicities of different PMs tested in TA98 with S9.
PM source Mean revertants/lg NFDPM in four experiments
W860 1.36 1.43 1.17 0.95
W861 1.36 1.55 1.32 1.04
W862 1.22 1.17+ 0.85* 0.72*
W863 1.00* 0.96* 0.81* 0.62*
W864 1.44 1.25 1.08 0.70*
* Signiﬁcantly different (p < 0.05) from respective values for W860 and W861.
+ Signiﬁcantly different (p < 0.05) from respective values for W861.3. Results
3.1. NRU
When PMs were tested at eight different concentrations in the
Neutral Red assay, in four different experiments, each PM showed
a concentration-related decrease in percent viability, which en-
abled IC50 values to be calculated.
The IC50 values obtained for the different PMs in all four exper-
iments are given in Table 2. It is clear that, for all of the PMs, when
tested in the same experiment at equivalent concentrations cor-
rected for nicotine-free dry particulate matter (NFDPM), the IC50
values were very similar. It is noticeable that there was variation
in relative cytotoxicities between different experiments. Also, in
several instances, the difference observed between IC50 values for
the same extract across four experiments was greater than the
differences between the IC50 values for the different extracts in
the same experiment.
When the mean IC50 concentrations (from the four experi-
ments) for each PM were analysed by one-way ANOVA, there were
no statistically signiﬁcant differences (p = 0.960). The IC50s of the
PMs from cigarettes with BT tobacco (W862–W864) were not dif-
ferent from those of PMs from cigarettes without BT tobaccoFig. 1. Bacterial mutagenicities of mainstream smoke particulates from test, control a
activation. Points plotted are the means of triplicate cultures ± standard error of measure
for the mean value. W860, W861, W
M4A.(W860–W861). The inclusion of BT tobacco in W862 did not
change the IC50, compared to its control (W861).3.2. SAL
All PMs induced concentration-related increases in revertants
in TA98 (Fig. 1), TA100 and TA1537 with S9. No mutagenicity
was detected in any strains without S9, or in TA1535 or TA102 with
S9.
For the responsive strains, the slopes of the linear part of the
concentration–responses were used to derive mutagenic potency
(number of mutants per unit concentration of chemical tested), ex-
pressed as revertants per lg NFDPM. The results are presented in
Tables 3–5.
In TA98 with S9, the reference PMs (2R4F and M4A) behaved
consistently with historical data, with 2R4F being more mutagenic
than M4A (Fig. 1). W863 (80% BT tobacco, with a carbon ﬁlter) in-
duced the lowest number of revertants with this strain in all 4
experiments. PMs from cigarettes with no BT tobacco (W860 and
W861) exhibited the highest mutagenic potency, except for one
experiment, when W864 exhibited the highest value. In pairwise
statistical comparison tests (Table 3), it was found that the muta-
genic potencies for W862 were signiﬁcantly lower (p < 0.05) than
the corresponding values for W861 in three of four experiments.
Cigarettes W861 and W862 had the same ﬁlter (CR20 and char-
coal), but W862 contained 80% BT tobacco. The other consistent
and statistically signiﬁcant differences, observed in all four TA98
experiments, were the signiﬁcantly lower mutagenic potencies
(p < 0.05) for W863, compared with the corresponding values fornd reference cigarettes, in Salmonella typhimurium strain TA98 with S9 metabolic
ment (SEM). Where error bars are not visible, they are contained within the symbol
862, W863, W864, 2R4F,
Table 4
Mutagenicities of different PMs tested in TA100 with S9.
PM source Mean revertants/lg NFDPM in four experiments
W860 0.45 0.35 0.50 0.36
W861 0.52 0.32 0.63 0.36
W862 0.51 0.33 0.48 0.37
W863 0.39 0.41 0.49 0.37
W864 0.55 0.36 0.40 0.44
No statistically signiﬁcant differences (p < 0.05) were observed.
Fig. 2. Micronucleus induction in V79 cells exposed to mainstream smoke particulates fro
two experiments. Points plotted are the means of duplicate observations ± SEM.
W863, W864.
Table 5
Mutagenicities of different PMs tested in TA1537 with S9.
PM source Mean revertants/lg NFDPM in three experiments
W860 0.30 0.16 0.16
W861 0.36 0.22 0.20
W862 0.20* 0.17 0.16
W863 0.19* 0.18 0.12+
W864 0.33 0.20+ 0.15
* Signiﬁcantly different (p < 0.05) from respective values for W860, W861 and
W864.
+ Signiﬁcantly different (p < 0.05) from respective value for W861.
R. Combes et al. / Toxicology in Vitro 26 (2012) 1022–1029 1025W860 and W861. The consistently lower mutagenic potencies
from cigarettes containing 80% BT tobacco was therefore observed
with two different ﬁlter types, pointing to the BT tobacco rather
than the ﬁlter type as the precursor to the lower mutagenic po-
tency of the PM. This is also consistent with established under-
standing of the minimal impact of carbon ﬁlters on the
composition of PM; carbon ﬁlters are effective adsorbents for the
vapour phase of cigarette smoke, which is minimally retained by
the ﬁlter pads used to trap PM (Baker, 1999). The mutagenic po-
tency of PMs from cigarettes containing 40% BT tobacco was not
consistently signiﬁcantly different from those of the control prod-
ucts, suggesting a threshold in BT tobacco content for a reduction
in mutagenic potency to be observed in this assay.
In the four experiments with TA100, in the presence of S9, only
very slight increases in revertants were seen, mainly for reference
sample 2R4F (Table 4). Mutagenicities of all the PMs in TA100 were
generally less than half their respective values that were obtained
withTA98.Only small differences inmutagenicpotencywere appar-
ent between sample extracts and experiments, and these were non-
signiﬁcant when subject to a one-way ANOVA comparison.m test, control and reference cigarettes, for 20 h without S9 metabolic activation, in
W860, W861, W862,
Table 6
Induction of micronuclei by PMs W860–W864.
PM source Induction of micronuclei (% MnBn/lg NFDPM)
3 h +S9 3 h S9 20 h S9
W860 0.0391,2,3 0.028 0.081 0.037 0.167 0.216
W861 0.065 0.031 0.089 0.038 0.146 0.221
W862 0.0541 0.032 0.0610,1 0.0364 0.1080 0.1190,1,3,4
W863 0.055 0.031 0.0570,1 0.038 0.0910,1,4 0.179
W864 0.0230,1,2,3 0.023 0.070 0.051 0.138 0.187
0 PM signiﬁcantly lower than W860 in a paired t-test.
1 PM signiﬁcantly lower than W861in a paired t-test.
2 PM signiﬁcantly lower than W862 in a paired t-test.
3 PM signiﬁcantly lower than W863 in a paired t-test.
4 PM signiﬁcantly lower than W864 in a paired t-test.
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lated increases in revertants were seen for all of the PMs, with ref-
erence sample 2R4F being the most mutagenic, followed by theFig. 3. Mammalian cell MF in L5178Y tk +/- cells exposed to mainstream smoke parti
activation, in two experiments. Points plotted are the means of duplicate cultures
W863, W864, 2R4F, M4A.other reference sample M4A, which was closely followed by the
other PMs, except for W862 andW863 which were mutagenic only
at the top concentration tested (Table 5). In a second experiment,
using the same strain and S9, reference sample 2R4F again gave
the highest revertant yield, but there was no clear concentration-
related increase in mutagenicity for any PM. Two further experi-
ments conﬁrmed weak concentration-related increases in rever-
tants for all of the PMs, with reference sample 2R4F giving the
clearest response. The mutagenic potencies of the extracts in
TA1537 were generally lower than they were in TA100, and
showed some variation between experiments. In one of the three
experiments with a concentration-related increase in revertants,
conducted with TA1537, W862 and W863 were signiﬁcantly less
mutagenic than W860, W861 and W864; and W863 and W864
also exhibited signiﬁcantly lower potencies than W861 in two
experiments.
In conclusion, there were no qualitative differences between
PMs in any strains. The PMs were also the same in terms of S9culates from test, control and reference cigarettes, for 24 h without S9 metabolic
± SEM. W860, W861, W862,
Table 7
Induction of TFT-resistant colonies by PMs W860–W864.
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mutagenic than the other PMs in strain TA98 with S9 activation.PM source MF/lg NFDPM
3 h +S9 3 h S9 24 h S9
W860 0.0137 0.0092 0.01692,3 0.0176 0.0658 0.0549
W861 0.0143 0.0144 0.0239 0.01212 0.04010 0.0395
W862 0.0096 0.0122 0.0263 0.0186 0.03730 0.0551
W863 0.0113 0.0095 0.0184 0.00230,1 0.03360 0.0376
W864 0.0112 0.0137 0.0268 0.0096 0.0536 0.0433
M4A 0.0102 0.0139 0.0323 0.0183 0.0535 0.0437
2R4F 0.0106 0.0143 0.0196A 0.0155 0.0339A 0.0060A
A Signiﬁcantly lower slope than M4A (p < 0.05).
0 Signiﬁcantly lower slope than W860 (p < 0.01) for W862 and W863 (24 h S9);
p < 0.05 for W861 and W863 (3 h S9).
1 Signiﬁcantly lower slope than W861 (p < 0.05).
2 Signiﬁcantly lower slope than W862 (p < 0.05).
3 Signiﬁcantly lower slope than W864 (p < 0.05).3.3. IVMNT
All PMs induced dose-related increases in cytotoxicity, and also
induced genotoxicity with and without S9 and at the different
treatment times. PMs increased the frequency of micronucleated
binucleate cells by more than 3-fold. In terms of dose and
%MnBn/lg NFDPM, the 20 h treatment without S9 was more sen-
sitive than the 3 h treatments. At 20 h without S9, W862 induced
fewer micronuclei than W860 and W861 in both experiments
(Fig. 2). This was statistically signiﬁcant in both experiments for
W860 and in one experiment for W861 (Table 6). At 3 h ± S9,
W862 induced fewer micronuclei than W861, in two experiments
(Table 6). The assay’s resolving power was limited by relatively
large variability within and between experiments, non-linear re-
sponses and >50% cytotoxicity at the higher doses in the 3 h treat-
ments. This may have contributed to the inconsistent differences
observed between PMs.3.4. MLA
Concentrations of test and reference PMs were selected in order
to provide asmany points as possible lying on the linear part of con-
centration–response curves, and to provide asmany concentrations
as possible that were common to each PM treatment, whilst allow-
ing treatment up to toxicity limiting dose levels. In some cases the
highest concentration levels were not selected for plating to deter-
mine viability and TFT resistance, or were excluded from analysis,
due to excessive toxicity (based on cell count data).
Statistically signiﬁcant increases in mutation frequency (MF) of
3- to 4-fold were observed with each of the PMs, on each experi-
mental occasion and with each of the treatment conditions em-
ployed (e.g. Fig. 3). In terms of dose and MF/lg NFDPM, the 20 h
treatment without S9 was themost sensitive, and the 3 h treatment
with S9 was the least sensitive. All PMs induced large colony mu-
tants, and in most cases a small increase in the induction of small
colonieswas observed (except forW860 andW861, in one 3 hwith-
out S9 treatment). In all cases a signiﬁcant linear trend was also
observed, indicating a concentration response relationship. These
results were therefore considered to be clear evidence for the geno-
toxicity of all samples in this assay system when using 3 h treat-
ments with and without S9, and 24 h treatments without S9.
When the responses of PMs were compared as colonies/lg
NFDPM, M4A was more mutagenic than 3R4F in both 20 h without
S9 experiments (Fig. 3, Table 7). The increases were statistically
signiﬁcant and consistent with historical data. W863 was less
mutagenic than W861 in both experiments of all three treatmentTable 8
Qualitative summary of in vitro data.
Sample In vitro test
SAL
S9 +S9
All strains TA102, 1535 TA98, 100, 1537
W860   +
W861   +
W862   +
W863   +
W864   +
M4A   +
3R4F   +
, inactive; +, active; nt, not tested.conditions, though a statistically signiﬁcant difference was
achieved in only one experiment. W862 was less mutagenic than
W861 in both 3 h with S9 experiments. Neither difference was sta-
tistically signiﬁcant. W862 was less mutagenic than W862 in one
3 h with S9 experiment and more mutagenic in the other. Neither
difference was statistically signiﬁcant. W862 was more mutagenic
thanW861 in both 3 h without S9 experiments. The difference was
statistically signiﬁcant in one experiment.4. Discussion
The results are summarised qualitatively in Table 8.
These results show that changing the tobacco type in the ciga-
rettes used did not alter the spectrum of activity detected in the
in vitro toxicity assays used (Table 8).
PMs from W860–W864 induced comparable dose-related cyto-
toxicities in the NRU. The inclusion of BT tobacco had no effect on
NRU cytotoxicity. W860–W864 PMs were genotoxic in the IVMNT
and MLA. W862 and W863 (both with 80%BT) were less genotoxic
than W861 (control), in some, but not all, experiments. The data
obtained with both of these assays were insufﬁciently consistent
to show any deﬁnitive quantitative differences in genotoxicity be-
tween the different types of cigarettes. In SAL, unlike the IVMNT or
the MLA, no mutagenicity was detected in the absence of S9. No
mutagenicity was detected in tester strains TA1535 or TA102 with
S9 with all PM samples, both test and reference, compared with
their mutagenicities in TA98, TA100 and TA1537.
These data broadly agree with observations made by previous
authors using PMs from a variety of tobaccos, ever since the origi-
nal observations of Kier et al. (1974). Thus, PM was genotoxic in a
variety of assays (Baker et al., 2004; Clive et al., 1997; Cobb et al.,
1989; DeMarini et al., 2008; DeMarini, 2004; Guo et al., 2011;IVMNT MLA NRU
S9 +S9 S9 +S9 S9
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + +
+ + + + nt
+ + + + nt
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Rickert et al., 2011, 2007; Roemer et al., 2004; 2002; Sato et al.,
1977). However, Putnam et al. (2002) did not ﬁnd a clear concen-
tration-related increase in cytotoxicity induced by PM in the NRU
assay, and Roemer et al. (2002) observed mutagenicity in Ames
strains TA98 and TA100 without S9.
Of note are the results of testing the PMs with S9 in strain TA98,
which showed a consistently lower mutagenic potency for W862
compared with W861. In three out of the four experiments, the
potencies were signiﬁcantly lower (p < 0.05), although the de-
creases were small. As W862 differed from W861 only in the
replacement of lamina tobacco with BT tobacco (Table 1), these
data suggest that the use of tobacco treated to remove some of
the protein resulted in a small, but consistent, decrease in muta-
genic potency with one tester strain. Furthermore, the mutagenic-
ity of W863 PM in strain TA98 with S9 was consistently lower than
those of W860 and W861. This is probably unrelated to the ﬁlter
additives in W861 and W863, because charcoal and CR20 have
no effect on PM (Baker, 1999). The more likely explanation is the
inclusion of 80% BT tobacco inW863. Reduced TA98mutagenicities
were observed for W862 andW863, but not with W864. W862 and
W863 contained 80% BT tobacco. W864 contained 40% BT tobacco.
This indicates that the reduction in bacterial mutagenicity is re-
lated to the amount of BT tobacco used.
The BT process involving protease digestion and water extrac-
tion, used to prepare the tobacco for the test samples, was shown
to remove more than half (59%) of the protein nitrogen, and more
than 40% of the total polyphenols from ﬂue-cured tobacco, while
12% of the nicotine is lost and total sugars are increased by 14%
(Liu et al., 2011). The reduction in nitrogen would be expected to
decrease mutagenicity (Mizusaki et al., 1977).
The treated tobacco also contained 1.9% glycerol, which was
added during the process, while the untreated tobacco contained
0.21%. While the differences in glycerol content would not be ex-
pected to alter toxicity or genotoxicity, the considerable reduction
in protein nitrogen should result in the generation of lower levels
of aromatic and heterocyclic amine protein combustion products,
generated on smoking, and considered to be the main cause of
mutagenicity in SAL (DeMarini, 2004; Van Duuren et al., 1960).
The BT process reduced the level of aromatic amines in smoke
(Liu et al., 2011). Previous observations on ﬂue-cured or burley to-
bacco treated in a similar way to that used for the present experi-
ments, resulted in an attenuation of mutagenicity of the resultant
PMs in strains TA98 (80%) and TA100 (50%) (Clapp et al., 1999). A
detailed assessment of the analysis of smoke products from the
tobaccos used by Clapp et al. (1999) would be required to account
for the discrepancies in the biological data. However, it is notewor-
thy that the process used by Clapp et al. (1999) with protease
digestion removed about 70% of the protein nitrogen from their
reconstituted tobacco, and, moreover, they did not report on any
other changes in constituents.
Overall, the results indicate that four in vitro tests, three of them
genotoxicity assays, found no qualitative differences between PM
samples obtained by individually smoking two reference cigarettes
and ﬁve samples of cigarettes with different tobacco blends and ﬁl-
ters, some of which contained tobacco treated to reduce levels of
protein nitrogen (Table 8).
In the Ames test, with strain TA98 and S9, there were small, but
signiﬁcant and repeatable, quantitative differences, suggesting that
BT tobacco reduced PM mutagenicity. These observations are con-
sistent with the hypothesis that reducing tobacco protein content
would reduce bacterial mutagenicity, without introducing any
new genotoxic or cytotoxic hazard.
Further toxicity testing is warranted to investigate the effects of
the tobacco treatment in more detail, and to add to the data al-
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